Tumor microenvironment evaluation to predict anti-PD-1 response of advanced gastric cancer: Results from a multicenter prospective clinical trial.

被引：0
|
作者：
Liao, Wangjun
Shi, Min
Zeng, Dongqiang
Luo, Huiyan
Xiao, Jian
Ye, Feng
Xiong, Hailin
Yuan, Xia
Huang, Yisheng
Li, Yongqiang
Huang, Na
Wu, Jianhua
Li, Shaowei
Zheng, Siting
Wu, Jiani
Sun, Li
Rong, Xiaoxiang
Wang, Chunlin
Guo, Jian
Deng, Qiong
机构：
[1] Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou, Peoples R China
[2] Sun Yat sen Univ, Canc Ctr, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Oncol, Guangzhou, Peoples R China
[4] Xiamen Univ, Dept Med Oncol, Affiliated Hosp 1, Xiamen, Peoples R China
[5] Huizhou First Hosp, Dept Med Oncol, Huizhou, Peoples R China
[6] Maoming Peoples Hosp, Dept Oncol, Maoming, Peoples R China
[7] Guangxi Med Univ, Dept Med Oncol, Canc Hosp, Nanning, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
415
引用
收藏
页码：415 / 415
页数：1
相关论文
共 50 条
  • [21] Oxaliplatin and irinotecan chemotherapy in advanced gastric cancer.: Final results of a multicenter phase II trial.
    Woell, E.
    Kuehr, T.
    Eisterer, W.
    Gattringer, K.
    Greil, R.
    Zabernigg, A.
    Hilbe, W.
    Thaler, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 195S - 195S
  • [22] Consensus Molecular Subtypes Efficiently Classify Gastric Adenocarcinomas and Predict the Response to Anti-PD-1 Immunotherapy
    Wu, Xiangyan
    Ye, Yuhan
    Vega, Kenneth J.
    Yao, Jiannan
    CANCERS, 2022, 14 (15)
  • [23] A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer
    Dong, Shuailei
    Wei, Chen
    Wang, Xueting
    Yang, Xinyi
    Shen, Wei
    Li, Shuyi
    Xu, Jiye
    Ma, Yijie
    Bie, Liangyu
    Yu, Wenyue
    Li, Ning
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [24] Apatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy
    Luo, Qicong
    Dong, Zinan
    Xie, Wen
    Fu, Xiaoteng
    Lin, Lingyun
    Zeng, Qiang
    Chen, Yinggang
    Ye, Guodong
    Chen, Maoli
    Hu, Huiyu
    Wang, Lin
    Xie, Yuanyuan
    Cai, Wangyu
    CELL REPORTS, 2023, 42 (05):
  • [25] Durable anti-tumor response of nivolumab (anti-PD-1 antibody) for platinum-resistant ovarian cancer; phase II clinical trial with nivolumab
    Hamanishi, J.
    Mandai, M.
    Matsumura, N.
    Abiko, K.
    Baba, T.
    Yamaguchi, K.
    Konishi, I.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 23 - 23
  • [26] Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti-PD-1 Therapy
    Fan, Xiaona
    Wang, Dan
    Zhang, Wenjing
    Liu, Jinshuang
    Liu, Chao
    Li, Qingwei
    Ma, Zhigang
    Li, Hengzhen
    Guan, Xin
    Bai, Yibing
    Yang, Jiani
    Lou, Changjie
    Li, Xiaobo
    Wang, Guangyu
    Li, Zhiwei
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [27] Astragaloside IV augments anti-PD-1 therapy to suppress tumor growth in lung cancer by remodeling the tumor microenvironment
    Wu, Tao
    Wu, Shikui
    Gao, Hui
    Liu, Haolei
    Feng, Jun
    Yi, Ge
    EUROPEAN JOURNAL OF HISTOCHEMISTRY, 2024, 68 (04):
  • [28] Frameshift events predict anti-PD-1/L1 response in head and neck cancer
    Hanna, Glenn J.
    Lizotte, Patrick
    Cavanaugh, Megan
    Kuo, Frank C.
    Shivdasani, Priyanka
    Frieden, Alexander
    Chau, Nicole G.
    Schoenfeld, Jonathan D.
    Lorch, Jochen H.
    Uppaluri, Ravindra
    MacConaill, Laura E.
    Haddad, Robert I.
    JCI INSIGHT, 2018, 3 (04)
  • [29] Effect of anti-PD-1 and anti-Id-1 combo on tumor response and survival in lung cancer
    Baraibar, Iosune
    Roman, Marta
    Lopez, Ines
    Ajona, Daniel
    Calvo, Alfonso
    Guruceaga, Elisabeth
    Corral, Jesus
    Lasarte, Juan Jose
    Vicent, Silvestre
    Gil-Bazo, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Reprogramming tumor immune microenvironment by milbemycin oxime results in pancreatic tumor growth suppression and enhanced anti-PD-1 efficacy
    Gaikwad, Shreyas
    Srivastava, Sanjay K.
    MOLECULAR THERAPY, 2024, 32 (09) : 3145 - 3162
12345